Although antibodies to other regions of the S protein can also play a role in virus neutralization,7 recent study indicates that the RBD-targeting NAbs are immunodominant during COVID-19.8 In this study, we validated sVNT using serum samples from 246 COVID-19 patients within 6 months post onset of symptom. Here, PROS1 is linked to COVID-19.